Skip to main content
ARCT
NASDAQ Life Sciences

Q3 Net Loss Halves to $7.4M as Arcturus Guides Cash Runway to 2028

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$9.34
Mkt Cap
$265.471M
52W Low
$5.5
52W High
$17.96
52W Position info
70% above low
Off High info
48% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

ARCT sits 70% above its 52-week low of $5.5.

Summary

Arcturus cut its third-quarter net loss to $7.4 million from $13.4 million a year earlier, or 26 cents a share, helped by a $12.0 million termination payment from CSL Seqirus that lifted revenue to $18.3 million from $17.2 million. R&D spending fell to $17.0 million from $23.3 million as the company wound down LUNAR-COVID and BARDA work and concentrated on its rare-disease pipeline. Cash stood at $184.8 million at quarter-end, down $46.1 million this year, and management says that funds operations through year-end 2028. The pipeline update follows the September 8-K with encouraging ARCT-810 Phase 2 interim data and the LUNAR 2.0 platform, which showed 38-fold greater potency than the key ARCT-810 lipid in non-human primates. ARCT-032 cystic fibrosis Phase 2 full data are slated for Q2 2027, with a Phase 3 go-decision from Thermo Fisher expected before then, and ARCT-2601 OTC deficiency dosing starts Q1 2027 with top-line data in H2 2027. The myNEO acquisition has closed, and KOSTAIVE marketing authorizations in the EU and UK have transferred to Arcturus ahead of a 2027 launch.

At the time of this announcement, ARCT was trading at $9.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $265.5M. The 52-week trading range was $5.50 to $17.96. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

ARCT - Latest Insights

ARCT
Nov 16, 2026, 8:30 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.52
Real-time Price: $7.55 info
Change: -$0.970 (-11%) info
Market Cap: $214.728M info
ARCT
Nov 05, 2026, 4:17 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.90
Real-time Price: $7.55 info
Change: -$2.35 (-24%) info
Market Cap: $214.728M info
ARCT
Sep 28, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $13.80
Real-time Price: $7.55 info
Change: -$6.25 (-45%) info
Market Cap: $214.728M info
ARCT
Sep 23, 2026, 4:29 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $13.90
Real-time Price: $7.55 info
Change: -$6.35 (-46%) info
Market Cap: $214.728M info
ARCT
Sep 23, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.90
Real-time Price: $7.55 info
Change: -$6.35 (-46%) info
Market Cap: $214.728M info